Tracer library / [177Lu]Lu-DOTA-AE105

[177Lu]Lu-DOTA-AE105

Also written as [Lu-177]Lu-DOTA-AE105

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated peptide (nonapeptide AE105 targeting uPAR)
Target / mechanism: Urokinase-type plasminogen activator receptor (uPAR) PMID 40326657
Clinical application: Cancer (various uPAR-expressing cancer types) PMID 40326657
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	—	>99%	DOTA-AE105	40326657 2025 Mol Pharm The respective amount of peptide (stock solution of 1 mM) and lutetium-177 were added to a 1/5 (v/v) mixture of sodium acetate (0.5 M) and HCl (0.05 M), followed by incubation of the reaction mixture at 95 °C for 10 min

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-AE105, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40326657. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40326657: 'DOTA-AE105'. Stage set/updated at stage 39 from PMID 40326657: 'Design and Preclinical Evaluation of Novel uPAR-Targeting Radiopeptides Modified with an Albumin-Binding Entity.'.